High dose human serum albumin for the treatment of acute ischemic stroke: A safety study

Neurocritical Care

Volumn 1, Issue 3, 2004, Pages 335-341

  Koch, Sebastian ^a   Concha, Mauricio ^a   Wazzan, Tarek ^a   Romano, Jose G ^a   Forteza, Alejandro ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Acute stroke treatment; Adverse events; Albumin therapy; Hypervolemic hemodilution; Neuroprotection

Indexed keywords

HUMAN SERUM ALBUMIN;

ADULT; AGED; ANAMNESIS; ATELECTASIS; CARDIOPULMONARY INSUFFICIENCY; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; DOSE RESPONSE; DRUG FATALITY; DRUG SAFETY; FEMALE; FLUID THERAPY; HUMAN; LUNG EDEMA; MALE; MEDICAL RECORD; MORTALITY; MULTIPLE REGRESSION; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; THORAX PAIN;

AGED; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEART DISEASES; HUMANS; LUNG DISEASES; MALE; MIDDLE AGED; NEUROPROTECTIVE AGENTS; RETROSPECTIVE STUDIES; RISK FACTORS; SERUM ALBUMIN; TREATMENT OUTCOME;

EID: 24644455227     PISSN: 15416933     EISSN: None     Source Type: Journal    
DOI: 10.1385/NCC:1:3:335     Document Type: Review

References (30)

1. Perez-Trepichio AD, Furlan AJ, Little JR, Jones SC. Hydroxyethyl starch 200/0.5 reduces infarct volume after embolic stroke in rats. Stroke 1992;23:1782-1790.
2. Yanaka K, Camarata PJ, Spellman SR, McDonald DE, Heros RC. Optimal timing of hemodilution for brain protection in a canine model of focal cerebral ischemia. Stroke 1996;27:906-912.
3. Tu YK, Heros RC, Karacostas D, et al. Isovolemic hemodilution in experimental focal cerebral ischemia. Part 2: effects on regional cerebral blood flow and size of infarction. J Neurosurg 1988;69:82-91.
4. Wood JH, Simeone FA, Fink EA, Golden MA. Hypervolemic hemodilution in experimental focal cerebral ischemia. Elevation of cardiac output, regional cortical blood flow, and ICP after intravascular volume expansion withlow molecular weight dextran. J Neurosurg 1983;59: 500-509.
5. Korosue K, Heros RC, Ogilvy CS, Hyodo A, Tu YK, Graichen R. Comparison of crystalloids and colloids for hemodilution in a model of focal cerebral ischemia. J Neurosurg 1990;73:576-584.
6. Cole DJ, Drummond JC, Patel PM, Nary JC, Applegate RL. Effect of oncotic pressure of diasporin cross-linked hemoglobin (DCLHb) onbrain injury after temporary focal cerebral ischemia in rats. Anesth Anal 1996;83:342-347.
7. Goslinga H, Eijzenbach V, Heuvelmans JH, et al. Custom-tailored hemodilution with albumin and crystalloids in acute ischemic stroke. Stroke 1992;23:181-188.
8. Scandinavian Stroke Study Group. Multicenter trial of hemodilution in acute ischemic stroke. Results of total patient population. Stroke 1987;18:691-699.
9. Italian Acute Stroke Study Group. Haemodilution in acute stroke: results of the Italian haemodilution trial. Lancet 1988;1: 318-321.
10. Hemodilution in Stroke Study Group. Hypervolemic hemodilution treatment of acute stroke. Results of a randomized multicenter trial using pentastarch. The Hemodilution in Stroke Study Group. Stroke 1989;20:317-323.
11. Aichner FT, Fazekas F, Brainin M, Pölz W, Mamoli B, Zeiler K. Hypervolemic hemodilution in acute ischemic stroke. The Multicenter Austrian Hemodilution Stroke Trial (MAHST). Stroke 1998;29:743-749.
12. Del Zoppo GJ. Why do all drugs work in animals but none in stroke patients? 1. Drugs promoting cerebral flow. J Intern Med 1995;237:79-88.
13. Gorelick P. Neuroprotection in acute ischaemic stroke: a tale of for whom the bell tolls. Lancet 2000;355:1949-1954.
14. Stroke Therpay Academic Industry Roundtable (STAIR). Recommendations for standards regarding preclinical neuroprotective and restorative drug development. Stroke 1999;30:2752-2758.
15. Belayev L, Busto R, Zhao W, Clemens JA, Ginsberg MD. Effect of delayed albumin hemodilution on infarct volume and brain edema after transient middle cerebral artery occlusion in rats. J Neurosurg 1997;87:595-601.
16. Belayev L, Liu Y, Zhao W, Busto R, Ginsberg MD. Human albumin therapy of acute ischemic stroke: marked neuroprotective efficacy at moderate doses and with a broad therapeutic window. Stroke 2001;32:553-560.
17. Belayev L, Saul I, Huh PW, et al. Neuroprotective effect of high-dose albumin therapy against global ischemic brain injury in rats. Brain Res 1999; 845:107-111.
18. Belayev L, Alosno OF, Huh PW, Zhao W, Zhao W, Ginsberg MD. Posttreatment with high-dose albumin reduces histopatholog-ical camage and improves neurological deficit following fluid percussion brain injury in rats. J Neurotrauma 1999;16:445-453.
19. Huh PW, Belayev L, Zhao W, Busto R, Saul I, Ginsberg MD. The effect of high-dose albumin therapy on local cerebral perfusion after transient focal cerebral ischemia in rats. Brain Res 1998;804:105-113.
20. Halliwell B. Albumin - an important extracellular antioxidant? Biochem Pharmacol 1988;37: 569-571.
21. Keaney JFJ, Simon DI, Stamler JS, et al. NO forms an adduct with serum albumin that has endothelium-derived relaxing factor-like properties. J Clin Invest 1993;91:1582-1589.
22. Emerson TE. Unique features of albumin: a brief review. Crit Care Med 1989;17:690-694.
23. Lennihan L, Mayer SA, Fink ME, et al. Effect of hypervolemic therapy on cerebral blood flow after subarachnoid hemorrhage: a randomized controlled trial. Stroke 2000;31:383-391.
24. Brown RB, Wiebers DO. Subarachnoid hemorrhage and unruptured intracranial aneursym. In: Ginsberg MD, Bogousslavsky J, eds. Cerebrovascular Disease. Pathophysiology, Diagnosis and Management. Blackwell Science, Malden, Massachusetts, 1998,1502-1531.
25. Caplan LR. Caplan's Stroke: a clinical approach. Butterworth Heinemann, Woburn, Massachu-setts, 2000, 54-57.
26. Hart R, Albers GW, Koudstaal P. Cardioembolic Stroke, in: Cerebrovascular Disease. Pathophys-iology, Diagnosis and Management (Ginsberg MD, Bogousslavsky J, eds.) Blackwell Science, Malden, Massachusetts, 1998,1392-1429.
27. Adams HP, Bendixen BH, Kapelle LJ, Biller J. Classification of subtypes of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST: Trial of ORG 10172 in acute ischemic stroke. Stroke 1993;24:35-41.
28. Goldstein LB, Chilukuri V. Retrospective assessment of initial stroke severity with the Canadian Neurological Scale. Stroke 1997;28:1181-1184.
29. Bushnell CD, Johnston DC, Goldstein LB. Retrospective assessment of initial stroke severity: comparison of the NIHSS and the CNS. Stroke 2001;32:656-660.
30. HES in acute Stroke Study Group. Hydroxyethyl starch for hypervolemic hemodilution in patients with acute ischemic stroke: a randomized, placebo-controlled phase II safety study. Cerebrovasc Dis 2002;14:33-41.